Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2010
At a glance
- Drugs Bryostatin-1 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 02 Mar 2010 Actual end date (June 2005) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Oct 2005 New trial record.